脑胶质瘤中异柠檬酸脱氢酶突变及其抑制剂研究进展

张娜, 黄嘉骏, 林婉君, 龙泽, 黄晓明, 杜晶晶, 马文哲

中国药学杂志 ›› 2019, Vol. 54 ›› Issue (3) : 165-169.

PDF(1133 KB)
中国药学杂志
PDF(1133 KB)
中国药学杂志 ›› 2019, Vol. 54 ›› Issue (3) : 165-169. DOI: 10.11669/cpj.2019.03.001
综述

脑胶质瘤中异柠檬酸脱氢酶突变及其抑制剂研究进展

  • 张娜, 黄嘉骏, 林婉君, 龙泽, 黄晓明, 杜晶晶, 马文哲*
作者信息 +

Current Progress in Isocitrate Dehydrogenase Mutations and Its Inhibitors in Gliomas

  • ZHANG Na, HUANG Jia-jun, LIN Wan-jun, LONG Ze, HUANG Xiao-ming, DU Jing-jing, MA Wen-zhe*
Author information +
文章历史 +

摘要

异柠檬酸脱氢酶突变存在于多数脑胶质瘤中,这是一种新的点突变,可导致原有的酶活性丧失,但却能催化α-酮戊二酸生成具有致癌作用的R-2-羟基戊二酸。异柠檬酸脱氢酶抑制剂能够减少R-2-羟基戊二酸的产生,诱导组蛋白去甲基化,从而抑制肿瘤发展。从2012年,首个抑制剂被发现,异柠檬酸脱氢酶突变体抑制剂就成为脑胶质瘤治疗领域的研究重点。2017年8月和2018年7月,异柠檬酸脱氢酶2突变体抑制剂enasidenib(AG-221)和异柠檬酸脱氢酶1突变体抑制剂ivosidenib(AG-120)相继被FDA批准上市,用于急性髓细胞性白血病的治疗,证实了异柠檬酸脱氢酶突变体作为肿瘤治疗靶点的可靠性。目前全球多个医药机构都在进行异柠檬酸脱氢酶抑制剂的研发,笔者对现有异柠檬酸脱氢酶抑制剂的研究现状进行综述。

Abstract

Glioma is a primary brain tumor produced by canceration of the glial cells in the brain and spinal cord, accounting for 74.6% of the malignant tumors in the central nervous system. Isocitrate dehydrogenase (IDH) is the rate-limiting enzyme of the tricarboxylic acid cycle and catalyzes the oxidative decarboxylation of isocitrate to produce α-ketoglutarate (α-KG). Its mutant (mIDH) is a new point mutation, not only lose its original function but also gain new activity: catalyzing the production of carcinogenic R-2-hydroxyglutarate (2HG) by α-KG. Isocitrate dehydrogenase inhibitors can reduce the production of 2HG and induce the demethylation of histones, thereby inhibiting tumor progression. Although discovered in 2008, the mIDH has become a tumor diagnostic marker and therapeutic target, mIDH2 and mIDH1 inhibitors for acute myeloid leukemia have been approved for marketing in 2017and 2018,respectively.For the treatment of acute myeloid leukemia, the reliability of isocitrate dehydrogenase mutants as tumor therapeutic targets was confirmed.At present, many pharmaceutical institutions around the world are conducting research and development of isocitrate dehydrogenase inhibitors.This article reviews the current research status of current IDH inhibitors.

关键词

脑胶质瘤 / 异柠檬酸脱氢酶突变 / R-2-羟基戊二酸 / 异柠檬酸脱氢酶抑制剂

Key words

glioma / isocitrate dehydrogenase mutation / R-2-hydroxyglutarate / isocitrate dehydrogenase inhibitors

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
张娜, 黄嘉骏, 林婉君, 龙泽, 黄晓明, 杜晶晶, 马文哲. 脑胶质瘤中异柠檬酸脱氢酶突变及其抑制剂研究进展[J]. 中国药学杂志, 2019, 54(3): 165-169 https://doi.org/10.11669/cpj.2019.03.001
ZHANG Na, HUANG Jia-jun, LIN Wan-jun, LONG Ze, HUANG Xiao-ming, DU Jing-jing, MA Wen-zhe. Current Progress in Isocitrate Dehydrogenase Mutations and Its Inhibitors in Gliomas[J]. Chinese Pharmaceutical Journal, 2019, 54(3): 165-169 https://doi.org/10.11669/cpj.2019.03.001
中图分类号： R965   

参考文献

[1] SIEGEL R L, MILLER K D, FEDEWA S A, et al. Colorectal cancer statistics, 2017 . CA Cancer J Clin, 2017, 67(3):177-193.
[2] OSTROM Q T, GITTLEMAN H, DE BLANK P M, et al. American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008-2012 . Neurooncology, 2015, 18(suppl 1):i1-i50.
[3] VAN MEIR E G, HADJIPANAYIS C G, NORDEN A D, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma . CA Cancer J Clin, 2010, 60(3):166-193.
[4] WEN P Y, KESARI S. Malignant gliomas in adults . N Engl J Med, 2008, 359(5):492-507.
[5] SHARMA H. Development of novel therapeutics targeting isocitrate dehydrogenase mutations in cancer . Current Topics Med Chem, 2018, 18(6):505-524.
[6] PARSONS D W, JONES S, ZHANG X, et al. An integrated genomic analysis of human glioblastoma multiforme . Science, 2008, 321(5897):1807-1812.
[7] YAN H,PARSONS D W, JIN G, et al. IDH1 and IDH2 mutations in gliomas . N Engl J Med, 2009, 360(8):765-773.
[8] HARTMANN C, MEYER J, BALSS J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas . Acta Neuropathol, 2009, 118(4):469-474.
[9] JOHNSON B E, MAZOR T, HONG C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma . Science, 2014, 343(6167):189-193.
[10] DANG L, YEN K, ATTAR E C. IDH mutations in cancer and progress toward development of targeted therapeutics . Annals Oncol, 2016, 27(4):599-608.
[11] MONDESIR J, WILLEKENS C, TOUAT M, et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives . J Blood Med, 2016, 7: 171-180.
[12] ZHAO S, LIN Y, XU W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α . Science, 2009, 324(5924):261-265.
[13] DANG L, WHITE D W, GROSS S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate . Nature, 2009, 462(7274):739-744.
[14] DANG L, SU S M. Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: from basic discovery to therapeutics development . Annual Review Biochem, 2017, 86(1):305-331.
[15] ZHENG S, WU Z S, WANG S, et al. Graphene-based materials for high-voltage and high-energy asymmetric supercapacitors . Energy Storage Mater, 2017, 6: 70-97.
[16] JIANG B, ZHAO W, SHI M, et al. IDH1 R132 mutant promotes tumor formation through downregulating p53 . J Biol Chem, 2018, 293(25):9747-9758.
[17] MADALA H R, PUNGANURU S R, ARUTLA V, et al. Beyond brooding on oncometabolic havoc in IDH-mutant gliomas and AML: current and future therapeutic strategies . Cancers, 2018, 10(2):49.
[18] SU Y T, PHAN F P, WU J. Perspectives on IDH mutation in diffuse gliomas . Trends Cancer, 2018, 32(10):1789-1797.
[19] ANDRONESI O C, KIM G S, GERSTNER E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy . Sci Transl Med, 2012, 4(116):116ra4.
[20] CHOI C, GANJI S K, DEBERARDINIS R J, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas . Nat Med, 2012, 18(4):624-629.
[21] ANDRONESI O C, LOEBEL F, BOGNER W, et al. Treatment response assessment in IDH-mutant glioma patients by noninvasive 3D functional spectroscopic mapping of 2-hydroxyglutarate . Clin Cancer Res, 2016, 22(7):1632-1641.
[22] FATHI A T, NAHED B V, WANDER S A, et al. Elevation of urinary 2-hydroxyglutarate in IDH-mutant glioma . Ocologist, 2016, 21(2):214-219.
[23] MILLER J J, SHIH H A, ANDRONESI O C, et al. Isocitrate dehydrogenase-mutant glioma: evolving clinical and therapeutic implications . Cancer, 2017, 123(23):4535-4546.
[24] LOUIS D N, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary . Acta Bropathol, 2016, 131(6):803-820.
[25] POPOVICI-MULLER J, SAUNDERS J O, SALITURO F G, et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett, 2012, 3(10):850-855.
[26] WANG F, TRAVINS J, DELABARRE B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation . Science, 2013, 340(6132):622-626.
[27] ROHLE D, POPOVICI-MULLER J, PALASKAS N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells . Science, 2013, 340(6132):626-630.
[28] INTLEKOFER A M, SHIH A H, WANG B, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations . Nature, 2018, 559(7712):125-129.
[29] WANG F, TRAVINS J, CHEN Y, et al. AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model. Am Soc Hematol, 2013, 122: 240.
[30] SHIH A H, SHANK K R, MEYDAN C, et al. AG-221, a small molecule mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo . Am Soc Hematol, 2014, 124: 437.
[31] MULLARD A. FDA approves first-in-class cancer metabolism drug . Nat Rev Drug Dis, 2017, 16(9):593.
[32] HANSEN E, QUIVORON C, STRALEY K, et al. AG-120, an oral, selective, first-in-class, potent inhibitor of mutant IDH1, reduces intracellular 2HG and induces cellular differentiation in TF-1 R132H cells and primary human IDH1 mutant AML patient samples treated ex vivo . Am Soc Hematol, 2014, 124: 3734.
[33] POPOVICI-MULLER J, LEMIEUX R M, ARTIN E, et al. Discovery of AG-120 (ivosidenib):a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers . ACS Med Chem Lett, 2018, 9(4):300-305.
[34] LEE W Y, CHEN K C, CHEN H Y, et al. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers . Biomed Res Int, 2014, 2014: 364625.
[35] ROHLE D, POPOVICI-MULLER J, PALASKAS N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells . Science, 2013, 340(6132):626-630.
[36] DAVIS M I, GROSS S, SHEN M, et al. Biochemical, cellular and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1 . J Biol Chem, 2014, 289(20):13717-13725.
[37] DINARDO C D, STEIN E M, DE BOTTON S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML . N Engl J Med, 2018, 378(25):2386-2398.
[38] KATHARINE Y E A. AG-881, a brain-penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies . Mol Targets Cancer Ther, 2017,17(1):126.
[39] CHO Y S, LEVELL J R, LIU G, et al. Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor . ACS Med Chem Lett, 2017, 8(10):1116-1121.
[40] CHATURVEDI A, HERBST L, PUSCH S, et al. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo . Leukemia, 2017, 31(10):2020-2028.
[41] ZHENG B, YAO Y, LIU Z, et al. Crystallographic investigation and selective inhibition of mutant isocitrate dehydrogenase . ACS Med Chem Lett, 2013, 4(6):542-546.
[42] DENG G, SHEN J, YIN M, et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule . J Biol Chem, 2014, 290(2):762-774.
[43] OKOYE-OKAFOR U C, BARTHOLDY B, CARTIER J, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia . Nat Chem Biol, 2015, 11(11):878-886.
[44] BROOKS E, WU X, HANEL A, et al. Identification and characterization of small-molecule inhibitors of the R132H/R132H mutant isocitrate dehydrogenase 1 homodimer and R132H/wild-type heterodimer . J Biomol Screen, 2014, 19(8):1193-1200.
[45] LAW J M, STARK S C, LIU K, et al. Discovery of 8-membered ring sulfonamides as inhibitors of oncogenic mutant isocitrate dehydrogenase 1 . ACS Med Chem Lett, 2016, 7(10):944-949.
[46] STEIN E M, ALTMAN J K, COLLINS R, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase Ⅰ study in patients with IDH2 mutation positive advanced hematologic malignancies . Am Soc Hematol, 2014, 124: 115.
[47] SAHA S K, GORDAN J D, KLEINSTIVER B P, et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma . Cancer Discov, 2016, 6(7):727-739.
[48] KIM H J, CHOI B Y, KEUM Y S. Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1 . J Cancer Prevent, 2015, 20(1):78-83.
[49] SCHUMACHER T, BUNSE L, PUSCH S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity . Nature, 2014, 512(7514):324-327.
[50] PELLEGATTA S, VALLETTA L, CORBETTA C, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma . Acta Neuropathol Commun, 2015, 3(1):4.
[51] REITMAN Z J, CHOI B D, SPASOJEVIC I, et al. Enzyme redesign guided by cancer-derived IDH1 mutations . Nat Chem Biol, 2012, 8(11):887-889.

基金

澳门科学技术发展基金资助(034/2015/A1)
PDF(1133 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉